Literature DB >> 14631560

Pathogenesis of Goodpasture syndrome: a molecular perspective.

Dorin-Bogdan Borza1, Eric G Neilson, Billy G Hudson.   

Abstract

Goodpasture (GP) syndrome is a form of anti-glomerular basement membrane (GBM) disease, in which autoantibodies bind to alpha3(IV) collagen in GBM causing rapidly progressive glomerulonephritis and pulmonary hemorrhage. The conformational GP epitopes have been mapped to 2 regions within the noncollagenous (NC1) domain of the alpha3(IV) chain. Recently, we described the molecular organization of the autoantigen in the native alpha3alpha4alpha5(IV) collagen network of the GBM. The crystal structure of the NC1 domain has revealed how the GP epitopes are sequestered in the native GBM. Further insight into the pathogenesis of disease has been obtained from better animal models. These advances provide a foundation for the development of new specific therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14631560     DOI: 10.1053/s0270-9295(03)00131-1

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  12 in total

1.  MicroRNA-127 inhibits lung inflammation by targeting IgG Fcγ receptor I.

Authors:  Ting Xie; Jiurong Liang; Ningshan Liu; Qingguo Wang; Yuhang Li; Paul W Noble; Dianhua Jiang
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

2.  Pulmonary hemorrhage complicating Goodpasture's disease in the course of pulmonary tuberculosis.

Authors:  Yao-Ko Wen; Kai-I Wen
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

3.  Zebrafish to humans: evolution of the alpha3-chain of type IV collagen and emergence of the autoimmune epitopes associated with Goodpasture syndrome.

Authors:  Brian A MacDonald; Malin Sund; Marianne A Grant; Kathleen L Pfaff; Kathryn Holthaus; Leonard I Zon; Raghu Kalluri
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

4.  Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent alphavbeta3 integrin conformers.

Authors:  Tracy Raymond; Elena Gorbunova; Irina N Gavrilovskaya; Erich R Mackow
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-18       Impact factor: 11.205

Review 5.  An unusual case of IgA-mediated anti-glomerular basement membrane disease.

Authors:  Yao-Ko Wen; Kai-I Wen
Journal:  Int Urol Nephrol       Date:  2012-03-29       Impact factor: 2.370

6.  Alport alloantibodies but not Goodpasture autoantibodies induce murine glomerulonephritis: protection by quinary crosslinks locking cryptic α3(IV) collagen autoepitopes in vivo.

Authors:  Wentian Luo; Xu-Ping Wang; Clifford E Kashtan; Dorin-Bogdan Borza
Journal:  J Immunol       Date:  2010-08-13       Impact factor: 5.422

7.  Human podocytes adhere to the KRGDS motif of the alpha3alpha4alpha5 collagen IV network.

Authors:  Corina M Borza; Dorin-Bogdan Borza; Vadim Pedchenko; Moin A Saleem; Peter W Mathieson; Yoshikazu Sado; Heather M Hudson; Ambra Pozzi; Juan Saus; Dale R Abrahamson; Roy Zent; Billy G Hudson
Journal:  J Am Soc Nephrol       Date:  2008-01-30       Impact factor: 10.121

Review 8.  Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.

Authors:  Tanya N Mayadas; George C Tsokos; Naotake Tsuboi
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

9.  Glutathione S-transferase Mu 2-transduced mesenchymal stem cells ameliorated anti-glomerular basement membrane antibody-induced glomerulonephritis by inhibiting oxidation and inflammation.

Authors:  Yajuan Li; Mei Yan; Jichen Yang; Indu Raman; Yong Du; Soyoun Min; Xiangdong Fang; Chandra Mohan; Quan-Zhen Li
Journal:  Stem Cell Res Ther       Date:  2014-01-30       Impact factor: 6.832

10.  Cerebral involvement in a patient with Goodpasture's disease due to shortened induction therapy: a case report.

Authors:  Christoph Preul; Jens Gerth; Sebastian Lang; Christoph Bergmeier; Otto W Witte; Gunter Wolf; Christoph Terborg
Journal:  J Med Case Rep       Date:  2009-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.